Ivermectin and Cancer: Analyzing the Three Proposed Mechanisms of Action
A deep dive into the pharmacology of why this repurposed medication is gaining interest in preclinical cancer research.
The exploration of repurposed medications—drugs already FDA-approved for one condition that may show efficacy in another—represents one of the most intriguing frontiers in modern oncology. Among these, Ivermectin, a long-standing antiparasitic, has generated significant conversation within patient communities and preclinical circles. While the clinical evidence remains in its infancy, the pharmacological interest is driven by several observed interactions between the drug and the molecular machinery of cancer cells. For Dan, a pharmacist with over two decades of experience and five years dedicated to researching Ivermectin, the goal is not to suggest patients abandon proven therapies, but to expand the vocabulary of treatment options. "I want you to be aware of treatment options that might otherwise not be mentioned to you," he notes, emphasizing that while large-scale human data is lacking, the "preclinical signals" published in medical literature warrant a closer look at how this drug interacts with malignant biology. By analyzing the "drug-target-disease process," researchers have identified three specific pathways where Ivermectin may disrupt cancer progression: the activation of programmed cell death, the induction of "self-cannibalization," and the inhibition of the pathways that sustain cancer stem cells.